Bioverativ (NASDAQ:BIVV) was downgraded by equities researchers at Jefferies Group from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, The Fly reports.
Other equities research analysts have also recently issued reports about the company. Zacks Investment Research raised Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 target price for the company in a research note on Monday, January 8th. Deutsche Bank set a $53.00 target price on Bioverativ and gave the company a “hold” rating in a research note on Monday, November 20th. Royal Bank of Canada lifted their target price on Bioverativ to $68.00 and gave the company a “market perform” rating in a research note on Thursday. Piper Jaffray Companies cut Bioverativ from an “overweight” rating to a “neutral” rating in a research note on Monday. Finally, Credit Suisse Group reissued a “neutral” rating and issued a $65.00 target price on shares of Bioverativ in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Bioverativ has a consensus rating of “Hold” and a consensus price target of $62.53.
Bioverativ (BIVV) traded up $39.68 during midday trading on Monday, hitting $103.79. The stock had a trading volume of 31,700,113 shares, compared to its average volume of 3,192,314. The firm has a market cap of $11,230.00 and a PE ratio of 25.38. Bioverativ has a one year low of $40.99 and a one year high of $104.30.
Bioverativ (NASDAQ:BIVV) last released its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.25. The company had revenue of $291.60 million during the quarter, compared to analysts’ expectations of $285.45 million. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The firm’s revenue for the quarter was up 27.2% compared to the same quarter last year. equities analysts predict that Bioverativ will post 2.69 earnings per share for the current year.
Several institutional investors have recently made changes to their positions in BIVV. Quotient Investors LLC acquired a new stake in shares of Bioverativ during the third quarter worth $420,000. Mutual of America Capital Management LLC acquired a new stake in shares of Bioverativ during the third quarter worth $5,062,000. Meeder Asset Management Inc. acquired a new stake in shares of Bioverativ during the third quarter worth $877,000. Rockefeller Financial Services Inc. acquired a new stake in shares of Bioverativ during the third quarter worth $1,480,000. Finally, State Treasurer State of Michigan acquired a new stake in shares of Bioverativ during the third quarter worth $2,323,000. 96.04% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Bioverativ (BIVV) Cut to “Hold” at Jefferies Group” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/22/bioverativ-bivv-cut-to-hold-at-jefferies-group.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.